Member Info for uxm484

You're just a desperate buyer.

The revenue comes from the deals. The lab is to support our projects.

The CEO is heavily invested with warrants. Expecting lots of value adding news.

You’re either trading, working for someone, or trying to fill a large order — there’s really no other explanation.

No one spends this much time trolling a stock for fun. And there’s definitely no reason to keep exaggerating the cash runway unless you’ve got an agenda.

Looking forward to the newsflow soon.

Porky is likely loading up in the background but telling us how bad Valirx is.

Maybe MM needs shares to complete orders.

Very important to read the RNS carefully.

@Viera, is it you that wants all the stock at this price? Are you one of the people loading up?

You actually sound like a desperate buyer who doesn’t want anyone else to buy as the information you are posting is far from accurate and is unlikely to be what you really believe.

🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀

The irony is that plenty of us recall Porky pushing the same no revenues nonsense back when APTA was 0.20p. He criticizes others over revenue, despite having invested in DDDD while it was posting losses of over £60 million annually.

The operating cash burn for Valirx is between 1-2 million pounds a year but the company is reaching key value-adding inflection points and deal completion stage. The revenue will be the upfront payment from a deal or further lab revenue. The main goal of the lab is to progress the in-house projects with the aim of achieving a deal.

As for viera: He will be back ramping soon enough.

viera

Posted in: VAL

Posts: 1,523

RE: Nick's Dilemma8 May 2025 06:42

“

https://valirx.com/evaluation-pipeline and l believ stingray will be the next spv after the 201 / clx prostate spv is updated by rns which should provide a clear value adding inflection point.”

If we get Stingray into an SPV we will be 1p . There is no way with 2 or 3 SPV that we will be a mkt cap of 1.5m pds. I would LOVE to see stingray taken up ,looks uber exciting malt cap of £3.5m with CLx and stingray ? Hmmmm even that may look far too cheap.

Bring it on Mark

Significant buying yesterday. Undervalued.

Need warrants executed. Target 1p.

Ready for take off 🚀🚀🚀🚀🚀

479,328,125

Great RNS.

Significant deals expected in 2026.

II support was strong at 9.5p.

Likely a larger buyer takes this back up.

Strong balance sheet, strong potential and huge margins.

Market cap based on potential.

This will almost certainly go up from here at some point so a decent buy.

Most buyers at 9.5 so they are unlikely to sell here.

Significant news in the coming weeks. We should hit 0.1 before the news so a nice buy.

Good news we could spike to 0.2.

Nice doubler at least I think.

25/30p takeover target inbound.

It is good news in the long run as value increases gives funding options in the future and at a premium. Reaction is likely mixed maybe slightly positive.

"We will also announce further material developments in regard to our Treasury policy shortly, where the market will be able to see our commitment to our dual gold/bitcoin strategy to grow shareholder value."

They have options for later on. Main thing funding secured in the long run.

Not done at a discount at a premium when needed.

I think we can head back to 3p in the short term.

20% premium so a positive.

Great news, nice rise expected today.

Lets Go.

The report concludes that targeted prostate cancer screening in the UK is practical, and that the UK National Screening Committee (NSC) should recommend a national programme for screening prostate cancer in high-risk men aged 45-69.

Furthermore, the report makes the case that new screening technologies, such as the EpiSwitch PSE blood test from Oxford BioDynamics, should be considered in the NHS as they promise greater accuracy, fewer unnecessary procedures, and can form the foundation for a population-wide programme. EpiSwitch PSE is named in the report, highlighting its strong potential to reduce false positives and minimise the need for further diagnostic procedures in low-risk cases.

The publication includes modelling for a future screening programme, which shows that adopting a reflex test with a balanced high specificity and sensitivity could reduce anticipated demand on MRI by more than 86% and biopsy procedures by 84%, while also saving costs for the NHS.